Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
The two-day event focused on the multi-faceted relationship of clinical research stakeholders and looked at bridging the academic and clinical research gap.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
This Bioforum will provide the latest insights on delivering increased speed, greater flexibility and enhanced quality while reducing the cost, and risks of navigating the evolving biopharma landscape
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
Subscribe To Our Newsletter & Stay Updated
